Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.
Robert N. Booher
Harold Hatch
Brian M. Dolinski
Thi Nguyen
Lauren Harmonay
Ali-Samer Al-Assaad
Mark Ayers
Michael Nebozhyn
Andrey Loboda
Heather A. Hirsch
Theresa Zhang
Bin Shi
Carrie E. Merkel
Minilik H. Angagaw
Yaolin Wang
Brian J. Long
Xianlu Q. Lennon
Nathan Miselis
Vincenzo Pucci
James W. Monahan
Junghoon Lee
Anna Georgieva Kondic
Eun Kyung Im
David Mauro
Rebecca Blanchard
Gary Gilliland
Stephen E. Fawell
Leigh Zawel
Alwin G. Schuller
Peter Strack
10.1371/journal.pone.0108371.t001
https://plos.figshare.com/articles/dataset/_Summary_of_Bliss_scores_and_sensitivity_to_dinaciclib_navitoclax_and_combination_treatment_/1196741
1<p>Synergy analysis after 18 hr treatment. vBliss: synergy (>0.1), additive (0.1–0.05). neutral (<0.05-0), antagonistic (<0).</p>2<p>Percent viability after 18 hour treatment with 100 nM dinaciclib, 1 µM navitoclax or the combination.</p>3<p>Information source. Cancer Cell Line Encyclopedia converted from log 2 to log10.</p><p>Summary of Bliss scores and sensitivity to dinaciclib, navitoclax and combination treatment.</p>
2014-10-07 03:18:02
MCL 1
antiapoptotic BCL 2 family member MCL 1
MCL 1 amplification
BCL 2 family member inhibitors
cdk
mechanism
dinaciclib antitumor response
abt
cell cycle progression